文献速递肾小球疾病

Tbet转录调节域核内递送改善狼疮倾向小鼠肾炎

Intranuclear delivery of the transcription modulation domain of Tbet-improved lupus nephritis in (NZB/NZW) F1 lupus-prone mice.
PubMed 文献 · Kidney Int · 2018-03-02

本研究制备了融合蛋白ntTbet-TMD,可进入细胞核并特异性抑制Tbet介导的转录。在(NZB/NZW)F1狼疮倾向小鼠中,ntTbet-TMD显著减轻肾炎严重程度,效果与甲泼尼龙相当,并减少脾和肾脏中Th1、Th2、Th17细胞数量及细胞因子分泌,同时增加脾Treg细胞及其抑制性细胞因子分泌。

要点

  • ntTbet-TMD可特异性抑制Tbet转录而不影响其他T细胞亚群分化。
  • ntTbet-TMD减轻狼疮倾向小鼠肾炎,效果与甲泼尼龙相当。
  • ntTbet-TMD减少脾和肾脏Th1/Th2/Th17细胞及细胞因子,增加Treg。

核心结论

  • ntTbet-TMD通过调节促炎微环境和再平衡T细胞亚群改善狼疮倾向小鼠肾炎。

研究设计与样本

  • 研究在(NZB/NZW)F1狼疮倾向小鼠中评估ntTbet-TMD的治疗效果。
  • ntTbet-TMD为Hph-1-PTD与Tbet的TMD融合蛋白,含DNA结合域和同种型特异域。

主要发现

  • ntTbet-TMD有效递送进入细胞核并特异性抑制Tbet介导的转录。
  • ntTbet-TMD不影其他T细胞亚群分化和T细胞活化信号事件。
  • ntTbet-TMD减轻肾炎严重程度,效果与甲泼尼龙相当。
  • ntTbet-TMD减少脾和肾脏中Th1、Th2、Th17细胞数量及细胞因子分泌。
  • ntTbet-TMD增加脾Treg细胞及其抑制性细胞因子分泌,而甲泼尼龙无此效应。

临床怎么用

  • ntTbet-TMD可能成为Th1介导自身免疫病的新免疫治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Excessive expression of Tbet and IFNγ is evidence of systemic lupus erythematosus (SLE) in lupus patients. In this study, the nucleus-transducible form of Transcription Modulation Domain (TMD) of Tbet (ntTbet-TMD), which is a fusion protein between Protein Transduction Domain Hph-1 (Hph-1-PTD) and the TMD of Tbet comprising DNA binding domain and isotype-specific domain, was generated to inhibit Tbet-mediated transcription in the interactomic manner. ntTbet-TMD was effectively delivered into the nucleus of the cells and specifically inhibited Tbet-mediated transcription without influencing the differentiation of other T cell subsets and signaling events for T cell activation. The severity of nephritis was significantly reduced by ntTbet-TMD as effectively as methylprednisolone in lupus-prone mice. The number of Th1, Th2 or Th17 cells and the secretion of their cytokines substantially decreased in the spleen and kidney of lupus-prone mice by ntTbet-TMD treatment. In contrast to methylprednisolone, the marked increase of Treg cells and the secretion of their immunosuppressive cytokine were detected in the spleen of (NZB/NZW) F1 mice treated with ntTbet-TMD. Thus, ntTbet-TMD can improve nephritis in lupus-prone mice by modulating the overall proinflammatory microenvironment and rebalancing T cell subsets, leading to new immune therapeutics for Th1-mediated autoimmune diseases.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Moon JS, Mun CH, Kim JH, et al. Intranuclear delivery of the transcription modulation domain of Tbet-improved lupus nephritis in (NZB/NZW) F1 lupus-prone mice. Kidney Int. 2018. PMID: 29409726. doi:10.1016/j.kint.2017.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。